Entera Bio reports Q3 net loss $2.4M; advances oral peptide pipeline with OPKO collaboration, Phase 3-ready EB613

Entera Bio Ltd.

2023-Q3 EPS reported $0.24

Net loss $2.4M ($0.08/share) vs $3.1M ($0.11) in Q3 2022; cash $7.6M sufficient into Q3 2024.
FDA concurred that 2-year Phase 3 study with BMD endpoint could support NDA for EB613 (oral PTH) in osteoporosis.
Collaboration with OPKO to develop oral GLP-2 for short bowel syndrome and oxyntomodulin for obesity; updates expected H1 2024.
EB612 (oral PTH for hypoparathyroidism) Phase 2a met endpoints; ongoing PK/PD study results expected end of 2023.
Operating expenses $2.4M, down from $2.9M YoY.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

Entera Bio Ltd. reported financial results for the third quarter ended September 30th, 2023.

Period: the third quarter ended September 30th, 2023
Result: reported results

Exact text from the filing

On November 14, 2023, Entera Bio Ltd., a company organized under the laws of the State of Israel (“we,” “us,” “our” or the “Company”), issued a press release announcing its financial results for the quarter ended September 30, 2023.

View on SEC.gov

Browse all earnings releases →

Entera Bio Ltd. filing history →

Source: SEC EDGAR

accession 0001178913-23-003664

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.